<DOC>
	<DOCNO>NCT00596648</DOCNO>
	<brief_summary>In Phase 1 study , purpose evaluate safety , tolerability , high safe dose multiple receptor tyrosine kinase inhibitor ( include VEGFR2 , MET , RET ) XL184 combination EGFR inhibitor erlotinib administer adult Non-Small-Cell Lung Cancer ( NSCLC ) . In Phase 2 study , purpose evaluate objective response rate daily oral administration XL184 without erlotinib subject NSCLC progress respond treatment erlotinib .</brief_summary>
	<brief_title>A Study XL184 ( Cabozantinib ) With Without Erlotinib Adults With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm NSCLC Stage 3b 4 NSCLC ( Phase 1 ) , Stage 3b 4 NSCLC ( Phase 2 ) Documented progressive disease follow prior RECIST response monotherapy erlotinib OR document progressive disease follow stable disease least 6 month monotherapy erlotinib ( Phase 2 ) Must tolerate erlotinib maximal dose administer Phase 2 ( high dose ) minimum 6 week Measurable disease per RECIST ( Phase 2 ) At least 18 year old ECOG performance status 0 1 Adequate organ marrow function Sexually active subject must agree use medically accept method contraception course study 3 month follow discontinuation study treatment ( exclude woman child bear potential men sterilize ) . Female subject childbearing potential must negative pregnancy test enrollment No diagnosis malignancy ( unless nonmelanoma skin cancer , carcinoma situ cervix malignancy diagnose ≥ 2 year previously , currently evidence disease ) . Capable understand comply protocol , write informed consent Received anticancer treatment within 4 week , except erlotinib , prior first dose ( Phase 1 ) In Phase 2 : subject receive : Small molecule inhibitor VEGFR2/KDR OR An investigational anticancer agent within 4 week first dose study drug OR An investigational agent target EGF EGFR time OR An approved agent target EGF EGFR ( exception erlotinib gefitinib ) time unless approve Exelixis OR Anticancer therapy within 4 week ( exception gefitinib erlotinib ) first dose study drug OR Prior therapy cMet inhibitor Not recover NCI CTCAE v.3 Grade ≤1 clinically significant adverse event due antineoplastic agent , investigational drug , medication administer prior study enrollment Symptomatic uncontrolled brain metastasis require current treatment , include steroid anticonvulsant History significant hematemesis recent history hemoptysis Presence cavitation , central lesion , lesion abut major blood vessel Intercurrent illness hypertension cardiac arrhythmias recent history significant disease congestive heart failure Pregnant breastfeeding Active bacterial viral infection require systemic treatment Allergy hypersensitivity component either XL184 erlotinib formulation Incapable understand comply protocol unable provide inform consent History idiopathic pulmonary fibrosis interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>